Splice variant microarrays have the potential to replace gene expression arrays for clinical markers, diagnostics, and target validation research due to greater specificity and biological relevance
Jivan Biologics and NimbleGen Systems have announced their partnership to make Jivan's splice variant array designs available on NimbleGen's high-density microarray platform.
"Jivan is proud to offer its full product line on NimbleGen's flexible and robust microarray platform," said Subha Srinivasan, CEO of Jivan Biologics.
"This partnership furthers our goal to become the platform-independent solution for high-throughput splice variant analysis".
Stanley Rose, president and CEO of NimbleGen Systems, commented: "Our collaboration with Jivan provides yet another example of an emerging measure of genome function or activity enabled by NimbleGen's platform".
"This product line nicely complements our whole genome ChIP-chip, CGH, Comparative Genome Sequencing, and Expression offerings, and further expands our integrated analytical capabilities also known as High-Definition Genomics".
Splice variant microarrays have the potential to replace gene expression arrays for clinical markers, diagnostics, and target validation research due to their greater specificity and biological relevance.
Jivan Biologics says it empowers scientists with new insight by providing a full catalogue of splice variant microarrays and PCR primer sets to benefit all stages of the drug development pipeline: biomarkers in blood, diagnostics, target validation, toxicology and basic research.
Customers must order splice variant arrays through Jivan.
NimbleGen Systems, a supplier of flexible high-density microarray products and services, is enabling a new era of high-definition genomics.
NimbleGen uniquely produces high-density arrays of isothermal long oligos that provide superior results for advanced genomic analysis methods such as CGH, ChIP, microbial comparative genome sequencing, and expression tiling.
NimbleGen's high-definition genomics enables scientists to obtain and integrate complex genomic data sets not previously accessible, providing a much clearer understanding of genome structure and function, and how this relates to biology and medicine.
This improved performance is made possible by NimbleGen's Maskless Array Synthesis (Mas) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesise high-density DNA microarrays.
